Tag: MONOGRAPH

  • Lamotrigine

    Phenyltriazine sodium channel blocker / mood stabilizer

    A phenyltriazine voltage-gated sodium channel blocker; uniquely effective for bipolar depression and a first-line maintenance mood stabilizer.

    Abstract

    Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; CAS 84057-84-1; molecular formula C9H7Cl2N5; molecular weight 256.09) is a phenyltriazine voltage-gated sodium channel blocker developed at Wellcome (now GSK) and approved by the FDA in 1994 under the trade name Lamictal. Mechanism: state-dependent inhibition of voltage-gated sodium channels (preferentially binding inactivated state), reducing release of presynaptic glutamate and aspartate. Secondary inhibition of high-voltage-activated calcium channels and weak antagonism at 5-HT3 receptors contribute to the broader profile. Distinct among anticonvulsants for efficacy in bipolar depression and maintenance mood stabilization (more effective at preventing depressive than manic episodes, opposite the lithium pattern). Plasma half-life is 25 to 33 hours alone, shortened by enzyme-inducing comedications. Hepatic metabolism is primarily glucuronidation. The principal limitation is a benign rash incidence of approximately 10 percent and Stevens-Johnson syndrome at approximately 1 in 1000, both reduced by slow titration over 4 to 6 weeks. Approved for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and bipolar I disorder maintenance. Used as the reference anticonvulsant mood stabilizer and as a clean voltage-gated sodium channel blocker.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Tamoxifen

    Selective estrogen receptor modulator (triphenylethylene)

    Abstract

    Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; CAS 10540-29-1; molecular formula C26H29NO; molecular weight 371.51) is a triphenylethylene SERM developed at ICI Pharmaceuticals (now AstraZeneca) and approved by the FDA in 1977 under the trade name Nolvadex. The compound is a tissue-selective estrogen receptor modulator: antagonist in breast tissue (the basis for breast cancer indications) and partial agonist in bone, liver, and uterus. The active metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen) generated via CYP2D6 is approximately 100-fold more potent than tamoxifen at ER binding and contributes substantially to clinical activity; CYP2D6 polymorphism affects clinical response. Plasma half-life is approximately 5 to 7 days for parent compound. Approved indications include adjuvant treatment of ER-positive breast cancer (premenopausal and postmenopausal), metastatic breast cancer, and breast cancer prevention in high-risk patients. Adverse events include endometrial cancer (rare), thromboembolism, and hot flashes. Used as the canonical SERM in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Thyrotropin-Releasing Hormone (TRH)

    Hypothalamic tripeptide (thyrotropin-releasing hormone)

    A hypothalamic tripeptide that triggers pituitary TSH release; used as a pharmacological probe for pituitary function and investigated for cognitive enhancement.

    Abstract

    TRH (thyrotropin-releasing hormone; pyroglutamyl-histidyl-prolinamide; CAS 24305-27-9; molecular formula C16H22N6O4; molecular weight 362.39) is a hypothalamic tripeptide that activates pituitary TRH receptors to trigger TSH release. Discovered independently by Schally and Guillemin in the late 1960s (Nobel Prize 1977). The compound is the smallest peptide hormone of the hypothalamic-pituitary axis. Pharmacologically, exogenous TRH has been used as a clinical probe of pituitary thyrotroph function (the TRH stimulation test, now largely supplanted by sensitive TSH assays). Beyond TSH release, TRH receptors are distributed throughout the CNS and TRH has direct effects on arousal, mood, and cognitive function; clinical trials in depression, ALS, and spinocerebellar ataxia have been mixed. Plasma half-life is approximately 5 minutes, severely limiting clinical use; analog development has produced taltirelin (approved in Japan for spinocerebellar degeneration) and other TRH receptor agonists with extended pharmacokinetics. Used as the canonical hypothalamic peptide for pituitary axis research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Sulbutiamine

    Synthetic disulfide thiamine derivative

    A lipophilic disulfide thiamine analog that crosses the blood-brain barrier; developed in Japan for asthenia and used as a nootropic.

    Abstract

    Sulbutiamine (isobutyryl thiamine disulfide; CAS 3286-46-2; molecular formula C32H46N8O6S2; molecular weight 702.89) is a synthetic disulfide derivative of thiamine (vitamin B1) developed in Japan in the 1960s and approved in several Asian and European markets under the trade name Arcalion. The compound is structurally a dimer of two thiamine molecules joined by a disulfide bridge, conferring high lipophilicity and improved blood-brain barrier penetration compared to thiamine itself. Mechanism: thiamine prodrug; sulbutiamine is metabolized to thiamine in the brain, raising central thiamine concentrations and supporting thiamine-dependent enzymes (transketolase, pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Clinical use is in psychogenic asthenia and as a nootropic; evidence is from clinical trials with mixed methodology. Plasma half-life is approximately 5 hours. Used as a lipophilic thiamine prodrug in research and nootropic communities.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cutamesine (SA-4503)

    Selective sigma-1 receptor agonist

    A selective sigma-1 receptor agonist developed for ischemic stroke recovery and major depressive disorder.

    Abstract

    Cutamesine (SA-4503; CAS 165377-44-6; molecular formula C19H30N2O2; molecular weight 318.45) is a selective sigma-1 receptor agonist developed at Santen Pharmaceutical and licensed to M’s Science. The compound has high sigma-1 affinity (Ki approximately 17 nM) with greater than 100-fold selectivity over sigma-2 and minimal off-target binding. Sigma-1 is a chaperone protein at the mitochondria-associated ER membrane that modulates ion channels, calcium signaling, and stress response. Phase 2 trials in ischemic stroke recovery (60 mg, 28 days starting within 72 hours of stroke) showed modest improvement; phase 2 in MDD showed mixed efficacy. Plasma half-life is approximately 5 hours. The compound is the cleanest available research probe for sigma-1 pharmacology. Used as the canonical selective sigma-1 agonist in academic research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Famotidine

    H2 receptor antagonist

    A second-generation H2 antihistamine; an acid-suppressing agent for peptic ulcers and GERD; investigated for anti-inflammatory and COVID-19 effects.

    Abstract

    Famotidine (3-({2-[(diaminomethylene)amino]-1,3-thiazol-4-yl}methylsulfanyl)-N-sulfamoyl-propanimidamide; CAS 76824-35-6; molecular formula C8H15N7O2S3; molecular weight 337.45) is a second-generation H2 receptor antagonist developed at Yamanouchi (now Astellas) and approved by the FDA in 1986 (Pepcid). The compound competitively inhibits H2 receptors on gastric parietal cells, reducing histamine-stimulated gastric acid secretion. H2 selectivity over H1 is greater than 1000-fold. Plasma half-life is approximately 2 to 4 hours; renal excretion is the principal clearance pathway. Approved indications: peptic ulcer disease, GERD, Zollinger-Ellison syndrome. The compound attracted attention during the COVID-19 pandemic after observational data suggested possible benefit; randomized controlled trials have produced mixed results, with proposed mechanisms including TMPRSS2 inhibition, sigma-1 modulation, and anti-inflammatory H2 antagonism on immune cells. Used as the canonical H2 antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Synephrine

    Adrenergic agonist (bitter orange alkaloid)

    p-Synephrine; a phenylethanolamine alkaloid from Citrus aurantium (bitter orange); a beta-3 adrenergic-preferring agonist used as a thermogenic supplement.

    Abstract

    Synephrine (p-synephrine, (R/S)-4-[1-hydroxy-2-(methylamino)ethyl]phenol; CAS 94-07-5; molecular formula C9H13NO2; molecular weight 167.21) is a phenylethanolamine alkaloid from Citrus aurantium (bitter orange) and other Citrus species. The compound is a structural analog of phenylephrine (the m-isomer) with a beta-3 adrenergic preference (relative to alpha-1 and beta-1) that distinguishes its pharmacology. The beta-3 activity drives thermogenesis and fat oxidation in adipose tissue, the basis for its supplement use as a weight-loss aid. Synephrine became prominent after the 2004 FDA ban on ephedra (which contained the more potent ephedrine). Clinical evidence for weight-loss effect is modest. Plasma half-life is approximately 2 hours. Used as a beta-3-preferring adrenergic agonist in metabolic research and supplement formulations.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Cetirizine

    Second-generation H1 antihistamine (peripheral)

    A second-generation peripheral H1 antihistamine; the principal active metabolite of hydroxyzine without CNS penetration.

    Abstract

    Cetirizine (2-[2-[4-[(R/S)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy]acetic acid; CAS 83881-51-0; molecular formula C21H25ClN2O3; molecular weight 388.89) is a second-generation H1 antihistamine developed at UCB and approved by the FDA in 1995 (Zyrtec). The compound is the principal active carboxylic acid metabolite of hydroxyzine; the addition of the carboxyl group eliminates blood-brain barrier penetration, producing peripheral H1 antagonism without the central sedating effects of hydroxyzine. H1 selectivity is high; minimal anticholinergic activity. Plasma half-life is approximately 8 hours; minimal hepatic metabolism (excreted largely unchanged renally). The compound has minor sedating effect in approximately 10 to 15 percent of users (slightly more than fexofenadine or loratadine), reflecting some BBB penetration. Approved indications: allergic rhinitis, urticaria, allergic conjunctivitis. Used as the canonical second-generation peripheral H1 antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Rolziracetam

    Bicyclic pyrrolidinone racetam

    A bicyclic piracetam analog with sparse published literature; primarily of historical and research-chemical interest.

    Abstract

    Rolziracetam is a bicyclic racetam analog with sparse published literature and no clinical development record. The compound features a fused bicyclic scaffold built on the pyrrolidinone core. Mechanism is presumed to overlap with piracetam pharmacology but has not been formally characterized. The compound is occasionally available from research chemical vendors; identity confirmation by mass spectrometry is essential before any investigational use. There is no published human pharmacokinetic data, no Phase 1 safety record, and no peer-reviewed dose-finding studies. This entry is included for completeness of the racetam class survey and as a marker that “racetam” as a class label spans well-characterized compounds (piracetam, levetiracetam) and obscure analogs with thin evidence bases.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Picamilon

    Niacin-GABA conjugate

    A Soviet-developed niacin-GABA conjugate (N-nicotinoyl-GABA) that crosses the blood-brain barrier and dissociates centrally to release both components.

    Abstract

    Picamilon (Pikamilon; N-nicotinoyl-GABA; CAS 34562-97-5; molecular formula C10H12N2O3; molecular weight 208.21) is a conjugate of niacin (nicotinic acid) and GABA developed in the Soviet Union in the 1970s. The niacin moiety provides blood-brain barrier permeability that GABA lacks; central hydrolysis releases both components. Niacin produces vasodilation and the GABA produces anxiolytic and mild sedative effects. The combination is approved in Russia for cerebrovascular insufficiency, anxiety, and migraine prophylaxis. Pharmacokinetics: rapid oral absorption; central hydrolysis to niacin and GABA; the niacin component is hepatically conjugated and excreted while GABA is metabolized through normal GABA pathways. The compound is sold as a research chemical/supplement in the United States though FDA has issued warnings against its sale as a dietary supplement.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.